Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

Xu L; Anderson J; Ferns B; Cook P; Wildfire A; Workman J; Graham S; Smit E

首页> 外文期刊>AIDS Research and Human Retroviruses >Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

【24h】

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

机译：天真和接受过抗逆转录病毒治疗的2型HIV患者中整合酶（IN）序列的遗传多样性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.

机译：已显示两种有效的整合酶抑制剂（IN-Is），拉尔格拉韦（RAL，MK-0518）和艾维格拉韦（EGV，GS-9137）是HIV-1的有效抑制剂，并且在HIV-1临床中已确定耐药性突变审判。在这项研究中，检查了来自11位HIV-2患者的序列的IN多态性。尽管临床分离株之间存在遗传变异，但未检测到与RAL和EGV耐药相关的主要突变。我们的研究提供了有关HIV-2对RAL和EGV的基因型易感性的基本信息，并支持将RAL和EGV视为治疗HIV-2感染患者的新治疗选择的建议。

著录项

来源
《AIDS Research and Human Retroviruses》 |2008年第7期|共5页
作者
Xu L; Anderson J; Ferns B; Cook P; Wildfire A; Workman J; Graham S; Smit E;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
RALA Gene; therapeutic aspects; Genetic; Integrase; HIV-2; 整合酶;

机译：RALA Gene;therapeutic aspects;Genetic;Integrase;HIV-2;整合酶;

相似文献

外文文献
中文文献
专利

1. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. [J] . Xu L, Anderson J, Ferns B, AIDS Research and Human Retroviruses . 2008,第7期

机译：天真和接受过抗逆转录病毒治疗的2型HIV患者中整合酶（IN）序列的遗传多样性。
2. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates [J] . PhuphuakratA., PasomsubE., KiertiburanakulS., AIDS Research and Human Retroviruses . 2012,第8期

机译：在泰国，以HIV 1型A / E亚型为主的未接受过治疗和有治疗经验的HIV 1型感染患者中，HIV 1型整合多态性
3. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. [J] . DeJesus E, Berger D, Markowitz M, JAIDS: Journal of acquired immune deficiency syndromes . 2006,第1期

机译：HIV-1整合酶抑制剂GS-9137（JTK-303）在未经治疗和有经验的患者中的抗病毒活性，药代动力学和剂量反应。
4. A Mathematical Model of Antiretroviral Therapy Evaluation for HIV Type [C] . Silvia Martorano Raimundo, Ezio Venturino, Hyun Mo Yang International Conference on Numerical Analysis and Applied Mathematics . 2009

机译：艾滋病毒型抗逆转录病毒治疗评价的数学模型
5. Genetic Diversity of RT-SHIV Viremia and Viral Reservoirs in a Non-human Primate Model of Human HIV-1 Highly Active Antiretroviral Therapy. [D] . Kauffman, Robert Clark. 2014

机译：RT-SHIV病毒血症和病毒库的遗传多样性在人类HIV-1高效抗逆转录病毒疗法的非人类灵长类动物模型中。
6. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China [O] . Min Chen, Yanling Ma, Song Duan, 2012

机译：滇西新诊断和未接受抗逆转录病毒治疗的HIV感染者的遗传多样性和耐药性：中国病毒重组的热点地区
7. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China [O] . 2012

机译：滇西新诊断和未接受过抗逆转录病毒治疗的HIV感染者的遗传多样性和耐药性：中国病毒重组的热点地区

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

摘要

著录项

相似文献

相关主题

期刊订阅